Cipla Ltd.

Cipla’s wholly owned subsidiary - Cipla (EU), UK (Cipla UK), has pursuant to the approval of the board of Cipla UK, made an additional investment of $3 million in Chase Pharmaceuticals Corporation Inc., US (Chase) towards full settlement of its obligation under the agreed arrangement for investment in Chase. Consequently, Cipla UK’s total investment in Chase would aggregate to approximately $5.12 million for a 16.7% stake on a fully diluted basis.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.